Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
ViewAttendees 1

C4B - Challenges in characterizing treatment response in oncology - Pitfalls and solutions

Wednesday, November 13, 2024
9:00 AM – 10:30 AM MST
Location: Sonoran Sky Ballroom 1 - 4

Disclosure(s):
Martin Bergstrand, PhD, ISOP member: Pharmetheus AB: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Pavan Vaddady, PhD: Merck & Co., Inc.: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Andrew C. Hooker, PhD, ISOP member: Pharmetheus AB: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)
Antoine Pitoy, PhD student: Association Nationale de la Recherche et de la Technologie: Grant/Research Support (Ongoing); Sanofi: Employment (Ongoing)

Presentations:

  • 9:00 AM – 9:30 AM MST
    Dose Selection and Optimization in Oncology: Focus on ADCs

    Speaker: Tushar Garimella, PhD, ISoP member, ACCP member (he/him/his) – Daiichi Sankyo Inc

  • 9:30 AM – 10:00 AM MST
    The flawed assumption of proportional hazards in oncology studies - What are the alternatives?

    Speaker: Andrew C. Hooker, PhD, ISOP member – Uppsala University

  • 10:00 AM – 10:30 AM MST
    Joint modeling of longitudinal biomarker data and progression free survival to accelerate drug approvals in oncology

    Speaker: Antoine Pitoy, PhD student – INSERM / Université Paris Cité